The combination of nivolumab and ipilimumab offers deep and sustained responses and improved overall survival in malignant uveal melanoma. Read More ›

Dual immunotherapy provides significant and durable benefits as first-line treatment and as neoadjuvant therapy in advanced melanoma. Read More ›